Prothena (PRTA)
(Delayed Data from NSDQ)
$8.18 USD
+0.12 (1.49%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $8.19 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRTA 8.18 +0.12(1.49%)
Will PRTA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRTA
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
Other News for PRTA
PRTA forms 20 Day Moving Average Resistance on September 18
Is PRTA ready to make a move? NR7 shows up after a flat session
PRTA forms NR7 on September 15
Is PRTA primed for downward momentum? Fell Below 20 Day Moving Average shows up after declining 2.61%
Crossed Above 20 Day Moving Average appears for PRTA after 1.51% move